Patents by Inventor Patrick J. Knerr

Patrick J. Knerr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIP DERIVATIVES AND USES THEREOF
    Publication number: 20240190938
    Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: February 3, 2023
    Publication date: June 13, 2024
    Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard DiMarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
  • GLP-1 AND GIP RECEPTOR CO-AGONISTS
    Publication number: 20230346961
    Abstract: Peptide co-agonists of the human GLP-1 and GIP receptors, long-acting derivatives thereof and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.
    Type: Application
    Filed: July 22, 2021
    Publication date: November 2, 2023
    Inventors: Patrick J. Knerr, Brian Finan, Fa Liu, Richard DiMarchi
  • CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY
    Publication number: 20230272029
    Abstract: Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.
    Type: Application
    Filed: July 22, 2021
    Publication date: August 31, 2023
    Inventors: Patrick J. Knerr, Brian Finan, Richard DiMarchi, Lars Linderoth
  • GIP derivatives and uses thereof
    Patent number: 11633459
    Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: April 25, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard Dimarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
  • CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY
    Publication number: 20220177538
    Abstract: Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.
    Type: Application
    Filed: July 22, 2021
    Publication date: June 9, 2022
    Inventors: Patrick J. Knerr, Brian Finan, Richard Dimarchi, Lars Linderoth
  • GIP DERIVATIVES AND USES THEREOF
    Publication number: 20220000982
    Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: May 3, 2019
    Publication date: January 6, 2022
    Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard Dimarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
  • GIP derivatives and uses thereof
    Patent number: 10604555
    Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particularly the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH). The peptides comprise a lysine residue at a position corresponding to position 24 of hGIP(1-31), and comprise a negatively charged modifying group attached to the epsilon amino group of the lysine residue.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: March 31, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard DiMarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
  • GIP DERIVATIVES AND USES THEREOF
    Publication number: 20190367578
    Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: May 3, 2019
    Publication date: December 5, 2019
    Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard DiMarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu